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Summary A human pancreatic adenocarcinoma was used to develop two histologically distinct
xenograft lines, one associated with high levels (180-2000 ng ml-') and one with low levels
(>2.0 <8.0 ng ml-') of serum carcinoembryonic antigen (CEA). A strong correlation was found
between tumour size and both circulating and tumour CEA levels in the former group, and also
correlation at the 5% level between tumour size and serum CEA in the latter. Administration of
either monoclonal or polyclonal '25I-anti-CEA antibody led to the formation of intravascular
antigen-antibody immune complexes in mice with high CEA levels, and these were rapidly
cleared by the liver, deiodination commencing within the first hour. Blood activity was reduced to
20% of the injected dose by 15 min, and by 24 h the radioactivity in all tissues except muscle was
significantly below that found in either the low CEA group or in mice without tumours. No
difference in radio-antibody clearance pattern was found between mice without tumours and the
group with low levels of serum CEA. In spite of higher levels of CEA within the tumour in mice
with elevated serum CEA, the rapid clearance of antigen-antibody complexes reduced tumour
localisation to one quarter of that seen in mice with low serum, and correspondingly low tumour,
CEA levels. Gamma-camera imaging confirmed these results. Possible implications to patient
selection and treatment are discussed.
Human neoplasms may produce and release substances refer-
red to as tumour markers into the circulation. Carcinoem-
bryonic antigen (CEA), a glycoprotein of 200,000 m.w. des-
cribed by Gold and Freedman in 1965, is a marker present in
epithelial neoplasms, e.g. colorectal, breast and lung, but also
at low levels in some normal tissues. Abnormally raised levels
of CEA in the serum (>10.0 ng ml-') can be assayed and so
help to monitor disease activity and patient management.
Early experiments demonstrated that radiolabelled
antibodies raised against CEA would localise to colorectal
tumours which could then be imaged in both animals
(Goldenberg et al., 1974; Mach et al., 1974) and man
(Goldenberg et al., 1978; Mach et al., 1980). However, the
administered antibodies are known to form immune com-
plexes with the circulating antigen (Primus et al., 1980;
Begent & Bagshawe, 1983), which should theoretically be
cleared rapidly by the reticuloendothelial system (RES) via
the Fc portion of the molecule (Mach et al., 1980). The
resulting loss of antibody from the blood pool should then
lower tumour accumulation and therefore reduce the imaging
potential of the neoplasms. This is at present a controversial
matter in man (Mach et al., 1980; Primus et al., 1980), and
few studies have been carried out in comparable animal
systems (Primus et al., 1976; Martin & Halpern, 1984; Hagen
et al., 1985).
The purpose of the present study was to investigate the
relationship between serum CEA levels, CEA levels within
the tumour, and tumour histology in a pancreatic tumour
xenograft model. We also investigated the effect of cir-
culating antigen on distribution and clearance of polyclonal
and monoclonal anti-CEA antibodies by both imaging and
tissue analysis.
Clearance patterns were compared with those produced by
administration of a second antibody raised against the anti-
CEA antibody and administered 6 h later. These also form
immune complexes in both animals (Chester et al., 1984;
Pedley et al., 1986) and man (Begent et al., 1987; Goldenberg
et al., 1987).
Materials and Methods
Xenografis
A moderately differentiated human adenocarcinoma of head
of pancreas, removed from a male patient of 52 years by
surgical resection, was used to develop a xenograft model
(LOBU) in female athymic (nu/nu) mice. This original xeno-
graft was associated with high levels of CEA both within the
tumour itself and also in the circulation. By continual sub-
cutaneous implantation from the original xenograft into
other mice, two distinct tumour lines were obtained, one
associated with high levels (180-2000 ng ml-') and the other
with low levels (>2.0 <8.0 ng ml-') of circulating CEA.
Studies were also carried out on mice bearing the MAWI
xenograft (Lewis et al., 1983), a colonic tumour which does
not secrete measurable CEA.
CEA measurements
Before each experiment, the mice were bled from the retro-
orbital venous sinus, and individual CEA measurements
assessed by the double-antibody method, using a Kemtek
3300 automated radioimmunoassay system. For tumour-
associated CEA measurements the tissue was weighed,
homogenised with an equivalent amount of physiological
saline at 4'C (Martin & Halpern, 1984), and the supernatant
assayed as above. A sample of each tumour was formalin
fixed, paraffin processed, and 5 ltm sections were stained by
immunohistochemistry to show CEA distribution using PK4S
(20 jig ml- ') in an avidin-biotin system (Kardana et al.,
1988).
Antibody clearance studies
These were carried out using either '251-labelled sheep poly-
clonal PK4S (Keep et al., 1983) or mouse monoclonal A5B7
(Pedley et al., 1987) antibodies to CEA. Both antibodies have
been used in clinical imaging studies (Begent et al., 1987).
Mice with high serum CEA were compared with those having
low antigen levels or no tumour.
We compared the results with a second antibody clearance
system. Donkey anti-sheep second antibody (2AB), donated
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by Burroughs Welcome, was administered intraperitoneally
to mice bearing the MAWI xenograft after allowing tumour
localisation of PK4S for 6 h. 2AB was given at 5 times the
dose of PK4S as this give superior clearance of anti-tumour
antibody than lower doses, while further increases produce
no significant improvement. Intraperitoneal delivery of 2AB
gives improved blood clearance of anti-CEA antibody when
compared with the intravenous route, possibly through pro-
longed diffusion into the circulation. The two antibodies
form complexes which are rapidly removed from the cirucla-
tion by the reticuloendothelial system (Begent et al., 1987).
We also investigated antibody localisation to the MAWI
tumour when the pancreatic xenograft with high serum CEA
was grown on the opposite flank of the mouse.
All antibody administration was via the tail vein at a
concentration of 20fLg 40pCi-' per mouse, using four mice
per group. The mice were bled and killed at times from
15 min to 7 days post-injection, and the following organs
removed for activity assessment by gamma counter (LKB
Wallac 1277 Gammamaster): blood, tumour, liver, kidney,
lung, spleen, colon, and muscle. Animals were given food
and water ad libitum, the latter containing 0.1% potassium
iodide during experiments to block thyroid uptake. Results
were analysed by Student's t test, 'significant' indicating a
calculated P value of less than 0.05.
Imaging
All groups were imaged at selected times by IGE Gemini
gamma-camera with a pinhole collimator and a Saturn com-
puter system.
Results
Xenografis
High-CEA pancreatic tumour This was a moderate to
poorly differentiated adenocarcinoma with small glandular
acini and areas showing solid sheets of tumour cells. Fre-
quent mitoses were seen, and there was some central necrosis.
A generalised strongly positive reaction for CEA was found
in the cytoplasm, glandular lumenal surface, and necrotic
debris (Figure la), and this was reflected in the assay results
from tumour homogenates (Table 1). There was a highly
significant correlation between tumour size and both serum
CEA (r = 0.90, P <0.001; Figure 2 and Table 1), and
tumour-associated CEA (r = 0.89, P <0.001; Table 1),
although considerable individual variation existed in the
data.
Low-CEA pancreatic tumour This was a moderately
differentiated adenocarcinoma with large glandular acini lined
with stratified epithelium. Frequent mitoseswereagainseen, but
there was more necrosis and fibrovascular stroma than in the
high-CEA tumour. The xenografts were mainly negative for
CEA, with some weak glandular membrane and focal cytoplas-
mic staining (Figure lb). There was correlation at the 5% level
between tumour size and serum CEA (r = 0.54, P <0.05;
Table I) although antigen levels remained below 8 ngml-', but
not between size and tumour-associated CEA (r = 0.39,
P>0.1; Table 1).
Clearance studies
Results obtained during the initial 24 h following radio-
antibody administration are shown in Figure 3. There was no
significant difference in PK4S clearance for mice with either
low serum CEA or with no tumour (Figure 3). Mice with
high CEA levels showed a significant reduction in circulating
antibody to 20% of the injected dose per gram by 15 min
post-injection (data not shown), later reflected by lower levels
in other tissues (Figure 3). Tumour activity fell to between 25
and 35% of that obtained for mice with low serum CEA by
24 h after injection. The pattern of tissue clearance for all
groups was maintained over 7 days (not shown). Although
Figure 1 Expression of CEA in pancreatic tumours with (a) high
levels of serum CEA (serum CEA = 672 ng ml-', tumour
CEA= llLgg-'; x61), and (b) low levels of serum CEA
(serum CEA=2ngmlh', tumour CEA=6fLgg-'; x38).
Immunohistochemistry of paraffin sections using anti-CEA
antibody in an avidin-biotin system. Counterstained with
haematoxylin.
Table I Relationship between tumourweight, serum CEA,
and tumour CEA, in mice with pancreatic xenografts
associated with either high or low levels of circulating
CEA
Tumour veight Serum CEA Tumour CEA
(g) (ngml-') (4lgg ')
High CEA
8.20
6.10
6.28
3.17
2.58
1.60
2.34
0.90
0.42
1.15
0.84
Low CEA
2.24
7.17
3.63
3.62
3.08
3.00
0.84
3.10
1.30
2.10
0.96
3.44
2.76
1.71
2166
1596
744
672
302
264
242
196
191
189
184
7
7
5
5
4
4
4
4
3
3
3
2
2
2
195.4
163.4
111.9
111.3
113.0
94.5
78.5
67.5
65.0
103.3
52.0
7.9
7.3
7.5
17.1
12.0
5.0
4.9
4.9
4.2
3.6
2.8
5.6
4.2
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culating antibody levels, while in the latter it was caused by a
slower decrease in blood levels accompanied by a rise in
tumour accumulation.
The antigen-antibody complexes formed in the mice and
demonstrated by FPLC (Pharmacia) were rapidly cleared by
the liver, which contained 25% of the injected dose per gram
by 15 min after antibody administration, and had double the
radioactivity levels seen in mice with low serum CEA by 1 h.
The increased liver activity was evident in gamma-camera
o scans at this time, and free iodide was localised in the
bladder, indicating that the complexes were already being
dehalogenated by the liver (Figure 4). By 3 h after adminis-
tration the activity in the liver had fallen to control levels,
o- and at 24 h all tissues except muscle in the high CEA group
showed significantly less activity than in the other two
groups. The reduction in background and tumour activity
was evident from gamma-camera scans using either poly-
clonal or monoclonal anti-CEA antibodies (Figure 5), both
o of which produced the same patterns of tissue clearance.
These results were compared with clearance patterns pro-
duced after administration of '25I-PK4S followed by an
unlabelled 2AB (100 l g) in mice bearing the MAWI xeno-
o- , * . graft. Antibody-antibody complexes were formed, and these
0 1 2 3 4 were also rapidly cleared from the circulation, but in this
Tumour weight (g) case by both liver and spleen (Figure 6), leaving all tissues
except colon and spleen (where dehalogenation was less
Figure 4 Gamma-camera image of nude mice bearing (a) pan-
creatic tumour with high serum CEA, (b) pancreatic tumour with
low serum CEA and (c) no tumour, 1 h after injection of 251
anti-CEA antibody.
Figure 5 Gamma-camera image of nude mice bearing (a) no
tumour, (b) pancreatic tumour with low serum CEA and (c)
pancreatic tumour with high serum CEA, 24 h after injection of
'251 anti-CEA antibody. Tumours are outlined.
Figure 2 Correlation of serum CEA levels with tumour size in
nude mice bearing pancreatic tumour xenografts with high levels
of serum CEA. Data from 37 mice. r= 0.90 (P <0.001).
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Figure 3 Effect of serum CEA on clearance of 1251 anti-CEA
antibody in a pancreatic xenograft model. Results are expressed
as percentage of antibody dose per gram of tissue, and are the
means of four mice. *, high CEA; M, low CEA; 0, no tumour.
Bars indicate s.d., not shown when <0.2.
antibody distribution differed significantly for mice with
either high or low CEA levels (Figure 3), very similar
tumour:blood ratios were produced. Values for mice with
high CEA were 0.15 at lh, 0.22 at 3h and 0.52 at 24h,
while the corresponding values for the low CEA group were
0.11, 0.22 and 0.47 respectively. The increase with time of the
former values resulted from the continuous decrease in cir-
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Figure 6 Effect of second antibody on anti-CEA antibody clearance, given 24 h after anti-tumour antibody. Results are expressed
as percentage of antibody dose administered per gram of tissue, and are the means of four mice. *, with 2AB; 0, without 2AB.
Bars indicate s.d., not shown when <0.2.
efficient than in the liver) with significantly reduced activity
by 24 h post-injection. Subsequent activity loss from the liver
was slower after 2AB clearance (15 h compared with less
than 3 h). Blood clearance was more efficient and loss of
tumour activity less pronounced for PK4S-antibody com-
plexes than for CEA-antibody complexes, leading to superior
tumour to blood ratios (3.4 at 3 h and 15.0 at 24 h). When
the non-secretory MAWI tumour was grown on the opposite
flank to the high-secreting pancreatic tumour, the rapid
clearance of CEA-antibody complexes drastically lowered
the dose of PK4S to the former from 8.0% to 2.2% g-' at
48 h (Figures 6 and 7).
Discussion
From an original pancreatic xenograft producing high levels
of both tumour associated and serum CEA, we have
developed two distinct tumour lines with different histology
and CEA production. There was a strong correlation
(r = 0.90) between tumour size (range 0.3-3.5 g) and serum
CEA in the model producing high levels of CEA. This is in
Figure 7 Gamma-camera image of nude mice bearing (a) colonic
tumour (left flank), (b) pancreatic tumour with high C A levels
(right flank), or (c) both tumours, 48 h after anti-CEA a ibody
administration. Tumours are outlined.
agreement with Mach et al. (1974) and also with Martin and
Halpern (1984), who found a correlation coefficient of 0.93
for colon tumour xenografts within the size range 0.2-1.7 g.
Absolute levels of CEA in the serum of patients also rise as
the tumour burden increases (Zamcheck et al., 1975). There
was also a highly significant correlation (r = 0.89) between
tumour size and tumour-associated CEA, which was not
found by Martin and Halpern (1984). Mice with low serum
antigen levels showed little increase in circulating or tumour-
associated CEA with tumour size (Table I). Although
tumour-associated CEA levels are thought to be important in
antibody targeting, mice with low levels of antigen in both
tumour and serum still localise 6.2% g-' of the injected dose
at 24 h (Figure 3). In mice with high levels of circulating
CEA, and correspondingly high concentrations of antigen in
the tumour, we also found some localisation of radioanti-
body (1.5% g-') in spite of rapid immune complex clearance
(Figure 3). This may be due to a gradient of increasing CEA
concentration from the serum to the tumour, or to the fact
that CEA-antibody complexes retain antigen binding sites
which can still react with the tumour if they are not cleared
from the circulation before contact (Mach et al., 1980).
The clearance of both mouse monoclonal and goat poly-
clonal CEA-antibody complexes was similar to that pro-
duced by administration of a second antibody, creating a
rapid drop in circulating activity followed by a significant
reduction in dose to other tissues. However, the more
efficient removal of circulating antibody by administration of
2AB, plus higher tumour values resulting from the time
allowed for localisation before initiation of clearance, pro-
duced higher tumour:blood ratios than were found after
CEA-antibody complex clearance. The majority of
antigen-antibody clearance was via the liver, in comparison
to antibody-antibody complexes which showed initial eleva-
tion of activity in both liver and spleen. It is possible that
quite different processes are involved for the two forms of
complex clearance, especially as activity loss from the liver is
at least 5 times slower, while blood clearance is faster,
when an antibody-antibody complex is involved.
Antibody-antibody complexes are thought to be cleared via
the RES (Mach et al., 1980; Begent et al., 1987) which
explains their presence in liver and spleen, both tissues rich in
phagocytic cells. However, it has been shown by Thornburg
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et al. (1980) that when antigen-antibody complexes are
formed in antibody excess galactose residues are exposed,
allowing rapid removal of these complexes from the circula-
tion by the galactose-specific receptors on the liver parenchy-
mal cells. Immune complexes formed in antigen excess have
much longer circulating half-lives, probably because two to
three antibody molecules per complex are required for strong
reaction with the receptor. In the present experimental system
there was a molar excess of antibody over antigen, which
could explain the rapid circulatory clearance via the liver.
When we lowered the antibody dose to 0.1 fgICi-' in mice
with high levels (800-1000 ng ml-') of circulating CEA, thus
creating an antigen excess, there was no clearance of immune
complexes (data not shown), which supports this theory. We
are in the process of investigating this further.
An alternative method of clearance for CEA-antibody
complexes may be the normal pathway for CEA itself, which
is also via the liver. This is a rapid process, and Shuster et al.
(1973) have shown that 50% of CEA administered to dogs
was removed from the blood within 5 min, while 55% had
accumulated in the liver by I h. Clearance was unrelated to
the reticuloendothelial system, as other tissues rich in
phagocytic cells (e.g. spleen and lung) showed only minute
levels of uptake. Sialic acid content of CEA did appear to be
important in hepatocyte uptake, and this varied not only
between tumours but within the same population. They
report at least two species of CEA with respect to biological
recognition and metabolism, one of which is cleared rapidly
via the liver, and one more slowly.
Both these mechanisms could explain why more radioanti-
body remains in the circulation after CEA-antibody than
after antibody-antibody complex formation (Figures 3 and
6), and why immune complexes remain in the blood of
patients. These complexes, in addition to the remaining free
radio-antibody which we observed and which is also found in
patients (Primus et al., 1980), may then be targeted to the
tumour and allow radio-immunolocalisation. CEA-antibody
complexes have been found in patients after treatment with
antibodies (Mach et al., 1980; Primus et al., 1980;
Goldenberg et al., 1980; Begent & Bagshawe, 1983), but this
has not been reported as leading to rapid circulatory
clearance or reduced tumour localisation. However, R.H.J.
Begent (personal communication) has found that anti-CEA
antibody is cleared more rapidly from the blood than certain
antibodies raised against a non-secreted antigen, and there is
also some evidence of activity accretion in the liver (Begent &
Bagshawe, 1983) both of which could result from immune
complex clearance. Because of the rapid dehalogenation of
CEA-antibody complexes in the liver shown in the present
study, and the variations in antibody distribution between
patients, it is possible that this early clearance has been
missed in some clinical studies. If patients have high levels of
serum CEA, there may be insufficient antibody excess for
rapid complex clearance during radio-immunolocalisation,
although the position could be reversed with the larger
antibody doses required for radio-immunotherapy. Although
Primus et al. (1980) found no obvious clearance of immune
complexes in patients with antibody excess, they state that
failure to localise one tumour may have been the result of
antigen neutralisation of radio-antibody. Other workers, who
also believe that high serum CEA levels may be detrimental
to tumour targeting, are now selecting patients with low
levels of serum CEA for radio-immunotherapy treatment
(Buchegger, personal communication). While we have shown
that removal of background activity may facilitate the
radiolocalisation of tumours by scanning, the concomitant
reduction in dose to the tumour would be detrimental to
radio-immunotherapy. In addition the raised liver activity
during immune complex clearance, although temporary,
could be harmful when a therapeutic dose is administered.
We have previously shown that the complex clearance pat-
terns found in xenograft studies after the administration of
second antibody were subsequently produced in patients
given the same treatment (Begent el al., 1987). The present
results, plus the above clinical findings, indicate the necessity
for further investigation into immune complexes and their
clearance in patients with raised levels of circulating antigen,
if their treatment involves the use of radio-antibodies raised
against that antigen. They also suggest that patients with low
levels of CEA in the tumour itself, often with correspon-
dingly low serum CEA, will still localise a targeted radio-
antibody and should not be excluded from localisation and
radio-immunotherapy studies.
The authors would like to thank Dr R.H.J. Begent for helpful
discussion and Dr P. Keep and G. Goka for skilled technical assis-
tance. The work was funded by the Cancer Research Campaign.
References
BEGENT, R.H.J. & BAGSHAWE, K.D. (1983). Radioimmunolocaliza-
tion of cancer. In Oncodevelopmental Markers: Biological, Diag-
nostic, and Monitoring Aspects, Fishman, W.H. (ed.) p. 167.
Academic Press: New York.
BEGENT, R.H.J., BAGSHAWE, K.D., PEDLEY, R.B. & 7 others (1987).
Use of second antibody in radioimmunotherapy. Nati Cancer
Inst. Monogr., 3, 59.
CHESTER, K.A., BEGENT, R.H.J., PEDLEY, R.B. & 4 others (1984).
The use of second antibody to improve selective localistion of
tumours: animal model studies. Br. J. Cancer, 50, 556.
GOLD, P. & FREEDMAN, S.O. (1965). Demonstration of tumour
specific antigen in human colonic carcinomata by tolerance and
absorption techniques. J. Exp. Med., 121, 439.
GOLDENBERG, D.M., PRESTON, D.F., PRIMUS, F.J. & HANSON, H.J.
(1974). Photoscan localization of GW-39 tumors in hamsters
using radiolabeled anticarcinoembryonic antigen immunoglobulin
G. Cancer Res., 34, 1.
GOLDENBERG, D.M., DELAND, F., KIM, P. & 6 others (1978). Use of
radiolabeled antibodies to carcinoembryonic antigen for the
detection and localization of diverse cancers by external photos-
canning. N. Engl. J. Med., 298, 1384.
GOLDENBERG, D.M., KIM, E.E., DELAND, F.H., BENNETT, S. &
PRIMUS, F.J. (1980). Radioimmunodetection of cancer with
radioactive antibodies to carcinoembryonic antigen. Cancer Res.,
40, 2984.
GOLDENBERG, D.M., SHARKEY, R.M. & FORD, E. (1987). Anti-CEA
enhancement of iodine-131 anti-CEA radioimmunodetection in
experimental and clinical studies. J. Nucl. Med., 28, 1604.
HAGAN, P.L., HALPERN, S.E., CHEN, A. & 5 others (1985). In vivo
kinetics of radiolabeled monoclonal anti-CEA antibodies in
animal models. J. Nuci. Med., 26, 1418.
KARDANA, A., TAYLOR, M.E., SOUTHALL, P.J., BOXER, G.M.,
ROWAN, A.J. & BAGSHAWE, K.D. (1988). Urinary gonadotrophin
peptide-isolation and purification, and its immunohistochemical
distribution in normal and neoplastic tissues. Br. J. Cancer, 58,
281.
KEEP, P.A., SEARLE, F., BEGENT, R.H.J. & 4 others (1983). Clearance
of injected radioactively labelled antibodies to tumour products
by liposomally-bound second antibodies. Oncodev. Biol. Med., 4,
273.
LEWIS, J.C.M., SMITH, P.A., KEEP, P.A. & BOXER, G.M. (1983). A
comparison of the content and immunohistochemical patterns of
CEA-like activity in human colorectal tumours and nude mouse
xenografts. Exp. Pathol., 24, 227.
MACH, J.-P., CARREL, S., MERENDA, C., SORDAT, B. & CEROTTINI,
J.-C. (1974). In vivo localisation of radiolabeled antibodies to
carcinoembryonic antigen in human colon carcinoma grafted into
nude mice. Nature, 248, 704.
MACH, J.-P., FORNI, M., RITSCHARD, J. & 5 others (1980). Use and
limitations of radiolabeled anti-CEA antibodies and their
fragments for photoscanning detection of human colorectal car-
cinomas. Oncodev. Biol. Med., 1, 49.
MARTIN, K.W. & HALPERN, S.E. (1984). Carcinoembryonic antigen
production, secretion, and kinetics in BALB/c mice and a nude
mouse-human tumor model. Cancer Res., 44, 5475.554 R.B. PEDLEY et al.
PEDLEY, R.B., DALE, R., BEGENT, R.H.J., BODEN, J.A., SEARLE, F &
CHESTER, K.A. (1986). A model for dosimetry in radioim-
munotherapy. Tumour Biol., 6, 356.
PEDLEY, R.B., BODEN, J., KEEP, P.A., HARWOOD, P.J., GREEN, A.J.
& ROGERS, G.T. (1987). Relationship between tumour size and
uptake of radiolabelled anti-CEA in a colon tumour xenograft.
Eur. J. Nucl. Med., 13, 197.
PRIMUS, F.J., WANG, R.H., COHEN, E., HANSEN, H.J. &
GOLDENBERG, D.M. (1976). Antibody to carcinoembryonic
antigen in hamsters bearing GW-39 human tumors. Cancer Res.,
36, 2176.
PRIMUS, J.F., BENNETT, S.J., KIM, E.E., DELAND, F.H., ZAHN, M.C.
& GOLDENBERG, D.M. (1980). Circulating immune complexes in
cancer patients receiving goat radiolocalizing antibodies to car-
cinoembryonic antigen. Cancer Res., 40, 497.
SHUSTER, J., SILVERMAN, M. & GOLD, P. (1973). Metabolism of
human carcinoembryonic antigen in xenogeneic animals. Cancer
Res., 33, 65.
THORNBURG, R.W., DAY, J.F., BAYNES, J.W. & THORPE, S.R. (1980).
Carbohydrate-mediated clearance of immune complexes from the
circulation. J. Biol. Chem., 255, 6820.
ZAMCHECK, N., DOOS, W.G., PRUDENTE, R., LURIE, R.B. & GOTT-
LIEB, L.S. (1975). Prognostic factors in colon carcinoma. Human
Pathol., 6, 31.